Combination treatment for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with cancer of the bile ducts (biliary tract cancer) that cannot be removed with surgery or has spread to other parts of the body.
- You must have already tried one standard chemotherapy (gemcitabine plus cisplatin) combined with an immunotherapy drug (a PD-1/PD-L1 inhibitor), and the cancer either got worse or you had to stop because of side effects.
- You must have at least one tumor that can be measured on a CT scan or MRI.
- You must be able to take care of yourself and be up and about more than half of your waking hours (ECOG performance status of 0 to 2).
- Your liver, kidney, and blood tests must be within certain levels, and you must not have had major recent surgery, radiation, or another cancer treatment within the past month.
- You cannot have significant heart problems, recent bleeding, blood clots, or a second cancer. You also cannot have an active infection, autoimmune disease, or be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a new combination of an oncolytic virus plus lenvatinib and toripalimab (immunotherapy drugs) compared with the standard chemotherapy FOLFOX for advanced bile duct or gallbladder cancer. The goal is to see if the new combination helps people whose cancer has progressed after one line of treatment.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new treatment approach for bile duct or gallbladder cancer that has not been treated before. It combines a freezing procedure (cryoablation) with an immunotherapy drug (Relaforp Alpha) and chemotherapy to see if it can shrink tumors or slow disease progression.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
This trial tests a procedure called cryoablation, which freezes and destroys cancer cells, combined with a targeted therapy drug (anlotinib) for people with advanced bile duct cancer that has not responded to earlier treatments. The goal is to see if this combination can slow the cancer's growth and improve outcomes.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.